FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1063-1064 March 13, 2003 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Keyomarsi, K. PubMed Citation

To the Editor: Keyomarsi et al. (Nov. 14 issue)¹ present the exciting and powerful finding that the levels of cyclin E in breast-cancer cells, as measured with the Western blot assay, correlate strongly with prognosis; however, there is a potential problem with their methods. The authors state, "Densitometric values for actin were used to standardize for equal protein loading." Are they aware that benign components of breast tissue such as myoepithelial cells have much higher actin levels than cancer cells? Many breast-cancer tissues will have some mixed benign component. A potential pitfall of using actin is that proteins from cells . . . [Full Text of this Article]

This article has been cited by other articles:

• Sieuwerts, A. M., Look, M. P., Meijer-van Gelder, M. E., Timmermans, M., Trapman, A. M.A.C., Garcia, R. R., Arnold, M., Goedheer, A. J.W., de Weerd, V., Portengen, H., Klijn, J. G.M., Foekens, J. A. (2006). Which cyclin e prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.. Clin. Cancer Res. 12: 3319-3328 [Abstract] [Full Text]